tbuckley/cabot-search huggingface dataset:
Abstract 1398: Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling
Authors: Satish Kumar Ramraj, Faizan H. Khan, Sheeja Aravindan, Mohan Natarajan, Terence S. Herman, Natarajan Aravindan
Journal: Cancer Research (2015)

Abstract High-risk neuroblastoma (HR-NB) presented with hematogenous metastasis is one of the most difficult cancers to cure with poor patient survival. Aggressive tumors contain populations of rapidly proliferating clonogens that exhibit stem cell properties, cancer stem cells (CSCs). Conceptually, CSCs that evade intensive multimodal therapy dictates tumor progression, relapse/recurrence and poor clinical outcomes. Herein, we investigated the plasticity and stem-cell related molecular response of aggressive metastatic neuroblastoma cells that fits CSC model. Well characterized clones of ‘metastatic site derive aggressive cells’ (MSDACs) from the manifold of metastatic tumors of clinically translatable HR-NB were characterized for their CSC fit. Alternated, yet stabilized (three generations) microenvironment simulation experiments with ‘serum-free stem cell medium’ to ‘growth medium with serum’ and vice versa identified flexible revocable plasticity. Signatures stem-cell related molecular responses consistent with phenotypic conversions are observed. Successive reintroduction to the favorable niche not only regained identical EMT, self-renewal capacity, pluripotency maintenance, and other stem-cell related signaling events, but also instigated additional events depicting the aggressive adaptive plasticity. Together, these results demonstrated the flexible plasticity of HR-NB MSDACs that typically fits in CSC model and further identified the intrinsic adaptivness of the successive phenotype switching that clarify the heterogeneity of HR-NB. Moreover, the continuous ongoing acquisition of stem-cell related molecular rearrangements may hold the key for the switch from favorable disease to HR-NB. Citation Format: Satish Kumar Ramraj, Faizan H. Khan, Sheeja Aravindan, Mohan Natarajan, Terence S. Herman, Natarajan Aravindan. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1398. doi:10.1158/1538-7445.AM2015-1398
Resprium (Librium-Theophylline-Ephedrine Compound) in the Treatment of Bronchial Asthma and Respiratory Allergy
Authors: J W THOMAS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The birth of a new lung syndrome?
Authors: Philip H. Quanjer
Journal: European Respiratory Journal (2016)

In a recent issue of the European Respiratory Journal , Harvey et al. [1] measured spirometry and transfer factor on two occasions in 105 smokers (74% African-Americans). Throughout the study, there was no evidence of respiratory disease. Whilst all had a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio >0.7, in 46, the measured transfer factor of the lung for carbon monoxide ( T LCO) was <80% predicted. In 15 out of 59 subjects with normal values, T LCO fell below 80% predicted during follow-up; in two, the FEV1/FVC ratio declined slightly below 0.7. Of the 46 subjects with T LCO <80% predicted, the FEV1/FVC ratio declined to <0.7. The authors conclude that a normal-spirometry, low- T LCO phenotype is a risk factor for developing chronic obstructive pulmonary disease. However, there are several flaws in this study that invalidate the conclusion. The proposal of a normal-spirometry, high- T LCO phenotype that predisposes to airway obstruction has several flaws <http://ow.ly/XRmz2>
Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients
Authors: H G Koenig, L K George, K G Meador
Journal: American Journal of Psychiatry (1997)

The purpose of this study was to examine antidepressant use by nonpsychiatrists in the treatment of depressed elderly medical inpatients.Patients aged 60 or older who were admitted to medical services at Duke Hospital were evaluated by a geropsychiatrist who used a structured psychiatric interview to identify major or minor depressive disorder. Medical records of depressed patients were reviewed for use of antidepressants and benzodiazepines before admission, during hospitalization, and on discharge. After discharge, depressed patients were contacted four times by telephone at 12-week intervals to inquire about medication use (median follow-up time = 45 weeks).Of 153 depressed patients, 40.5% received antidepressants at some time during their hospital stay or follow-up period, 25.5% received only benzodiazepines, and 34.0% received neither. The most commonly prescribed antidepressant was amitriptyline (45.2% of treated patients), administered at an average maximum dose of 49 mg/day. Only 15 of 114 untreated depressed patients started antidepressant therapy during hospitalization (nine with amitriptyline). Of 91 depressed patients who did not receive antidepressants either before admission or during hospitalization, only 11% received any antidepressant therapy during the median 11-month follow-up; again, half were treated with amitriptyline at doses of 10-30 mg/day. Intensity of antidepressant therapy was predicted by severity of depressive symptoms, history of psychiatric problems, and higher income.A relatively low proportion of depressed older medical inpatients receive treatment with antidepressants. Patients treated with antidepressants often receive potentially dangerous tertiary tricyclics at inadequate doses. Unless depression is identified and treated during medical hospitalization, it is unlikely to be treated adequately after discharge.
Evidence review for the 2016 International Ankle Consortium consensus statement on the prevalence, impact and long-term consequences of lateral ankle sprains
Authors: Phillip A Gribble, Chris M Bleakley, Brian M Caulfield, Carrie L Docherty, François Fourchet, Daniel Tik-Pui Fong, Jay Hertel, Claire E Hiller, Thomas W Kaminski, Patrick O McKeon, Kathryn M Refshauge, Evert A Verhagen, Bill T Vicenzino, Erik A Wikstrom, Eamonn Delahunt
Journal: British Journal of Sports Medicine (2016)

Lateral ankle sprains (LASs) are the most prevalent musculoskeletal injury in physically active populations. They also have a high prevalence in the general population and pose a substantial healthcare burden. The recurrence rates of LASs are high, leading to a large percentage of patients with LAS developing chronic ankle instability. This chronicity is associated with decreased physical activity levels and quality of life and associates with increasing rates of post-traumatic ankle osteoarthritis, all of which generate financial costs that are larger than many have realised. The literature review that follows expands this paradigm and introduces emerging areas that should be prioritised for continued research, supporting a companion position statement paper that proposes recommendations for using this summary of information, and needs for specific future research.
Importance of the Infecting Dose on Growth Patterns of Rous Sarcoma Virus (RSV) in Chick Brain&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Frank J. Rauscher, Vincent Groupé
Journal: JNCI Journal of the National Cancer Institute (1960)

The growth curves of Rous sarcoma virus (RSV) in chick brain paralleled those of many nononcogenic animal viruses only when large doses were used. First, virus disappeared very rapidly from the brain after intracerebral inoculation. This was followed by a stationary phase of varying duration, during which the infective virus content of the brain remained low. Finally, the relative potencies of brain tissue increased logarithmically and reached their peak in moribund chicks. Growth curves were obtained for each of six different doses of RSV. It was found that the length of the stationary phase, the time to double-extractable potency, and the maximum potency attained in brain tissue were directly related to the amount of virus contained in the infecting inoculums. It is suggested that the dependence of the pathogenesis of disease on the amount of RSV contained in the infecting dose represents a basic difference between at least one tumor virus and the nononcogenic viruses.
Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France)
Authors: D Lévy-Bruhl, A Perrocheau, M Mora, M K Taha, S Dromell-Chabrier
Journal: Eurosurveillance (2002)

In the department of Puy-de-Dôme, France, 17 cases of invasive meningococcal disease C were notified between March 2001 and the first week of 2002. Among the 15 confirmed cases, 11 (73%) were serogroup C, 2 (13%) serogroup B, and 2 could not be identified. The rapid increase in the number of cases in a period of low endemicity for the rest of the country and the severity of the disease (case fatality ratio 27%, purpura fulminans 64%) led the health authorities to initiate a vaccination campaign targeting children and young adults from 2 months up to 20 years living in a limited area of the department. Around 80 000 people were immunised between 16/01/02 and 09/02/02. More than half of the 1390 immediate side effects were headache and dizziness. As of mid-March, no further case of meningococcal disease has been notified since 6 January.
Quality and Safety in Health Care, Part V
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2015)

The Institute of Medicine report Crossing the Quality Chasm: A New Health System for the 21st Century focused on quality issues generally in health care, not only on mistakes. It made numerous recommendations for improving health care, including 6 aims and 10 rules to guide policy makers. This was intended to help redesign health care. However, the authors of the report did not attempt to provide all the answers because they realized that innovation was important and that they could not foresee all the sociopolitical forces and technological and research breakthroughs in the future.
Endoscopic band ligation for gastric antral vascular ectasia: time for a new indication?
Authors: Chiara Marzano, Maddalena Zippi, Giampiero Traversa
Journal: Endoscopy (2016)

We read with great interest the study by Zepeda-Gómez et al. [1] on the treatment of gastric antral vascular ectasia (GAVE) with endoscopic band ligation (EBL). Successful therapy for GAVE is often a challenge and the use of EBL may be a good idea to improve the treatment of this rare but significant cause of acute or chronic gastrointestinal blood loss. We would like to share our experience with a patient who had GAVE and was treated in the same way, in order to strengthen some important key messages emerging from this work.
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV
Authors: Susanne Saussele, Michael Lauseker, Martin C. Müller, Alois Gratwohl, Dietrich Beelen, Donald W. Bunjes, Rainer Schwerdtfeger, Hans-Jochem Kolb, Anthony D Ho, Christiane Falge, Ernst Holler, Günther Schlimok, Axel R. Zander, Renate Arnold, Lothar Kanz, Robert Dengler, Claudia Haferlach, Brigitte Schlegelberger, Susanne Schnittger, Lida Kalmanti, Ulrike Proetel, Benjamin Hanfstein, Wolf-Karsten Hofmann, Joerg Hasford, Andreas Hochhaus, Markus Pfirrmann, Rüdiger Hehlmann
Journal: Blood (2014)
Inhibition of Insulin-Binding to Tissues by p-Hydroxymercuribenzoate and n-Ethylmaleimide
Authors: J E WHITNEY, O E CUTLER, F E WRIGHT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0801 Decrease Inflammation but not Modification of Traditional Cardiovascular Diseases Risk Factors Improves Arterial Wall State After Anti-TNF Treatment in Psotiatic Arthtitis Patients
Authors: E. Markelova, E. Loginova, D. Novikova, I. Kirillova, S. Gluhova, T. Korotaeva
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Psoriatic arthritis (PsA) patients (pts) have increased cardiovascular disease (CVD) risk due to combination of traditional risk factors (TRF) and autoimmune inflammation. Anti-TNF therapy is an effective in PsA but it9s cardiovascular effects has still limited data. <h3>Objectives</h3> To study the effects of anti-TNF therapy Adalimumab (ADA) on disease activity, carotid intima-media thickness (c-IMT), parameters of arterial stiffness (AS), ambulatory blood pressure monitoring (AMBP) and CVD TRFs in PsA pts. <h3>Methods</h3> 20 (F.-14) PsA pts, according to the CASPAR criteria, mean age 45.5 [39.5; 49] years (yrs.), PsA duration – 7.7 [1.5; 22] yrs, DAS 4.61 [2.92; 6.29], C-reactive protein (CRP, mg/l) 27.2 [9.7; 33.7] were included. All pts were treated by ADA 40 mg every other week up to 3 months. At baseline and after 3 months of therapy all pts underwent standard clinical examination, DAS, CRP, total cholesterol (TC), triglycerides (TG), low and high density lipoproteins (LDL/HDL), c-IMT, AS and ABPM. ABPM was performed by standard procedure. AS were measured by Pulce Trace Device (PT 2000, Micro Medical, UK); carotid-femoral pulse wave velocity (PWVcf) were performed with a 4 MHz Doppler probe; index of wave reflection (regidity index) (RI, %) were performed by a digital volume photo-plethysmography transducer; c-IMT were measured using a high-resolution B-mode ultrasound machine. Me [Q25;Q75], Wilcoxon9s rank sum test were calculated. All p less then 0.05 considered to statistical significance. <h3>Results</h3> By 3 months of therapy DAS/C-RP significantly decreased to 1.6 [1.3; 1.9]/1,8 [0,8; 3,1] accordingly, p=0.001. DAS remission (&lt;1.6) was achieved in 94% of pts. By the end of therapy TC and TG significantly increased from 4.9 [4.5; 5.9] to 5.6 [4.9; 6.3] mmol/l and from 0.8 [0.7; 1.4] to 1.1 [0.9; 1.4] mmol/l accordingly, (for all p=0.03). We didn9t find significant differences between baseline and after treatment levels of LDL/HDL level: from 3.3 [2.8; 4.1] to 3.6 [3.3; 4.1] mmol/l and from 1.3 [1.2; 1.5] to 1.3 [1.2; 1.6] mmol/l accordingly, (p=0.13-0.6). By the end of treatment AMBPs parameters didn9t significant change as well. By the end of therapy c-IMT significant decreased from 0.8 [0.74; 0.85] mm to 0.73 [0.58; 0.77] mm, p=0.01. By 3 months of therapy all AS parameters significant decreased: PWVcf from 9.9 [7.7; 17.7] to 9.2 [7.4; 10.6] m/s, (p&lt;0.05), RI from 69.5 [58.0; 74.0] % to 49.5 [44.0; 64.0] % (p&lt;0.05). <h3>Conclusions</h3> Anti-TNF treatment ADA improves arterial wall state by decrease inflammation but not by modification of CVD TRFs. These dates confirmed the idea that inflammation involved in acceleration of atherosclerosis in PsA pts. <h3>Disclosure of Interest</h3> None declared
Percutaneous endoscopic gastrostomy assisted by laparoscopy: is it a valid choice?
Authors: Laura Uribarri González, José Iglesias Canle, Purificación Parada Gonzalez, Andrea Castiñeira Perez, J. Domínguez-Muñoz
Journal: Endoscopy (2016)

Percutaneous endoscopic gastrostomy (PEG) has become the procedure of choice for enteral feeding, with a relatively low risk of complications and a high success rate in 95 % of cases [1]. Currently it offers a new approach to continuous infusion with levodopa in selected patients with Parkinson's disease. Nevertheless, certain patient characteristics can absolutely contraindicate the procedure [2] [3].
Early Alzheimer's Disease
Authors: Francisco J Ruiz-Ruiz
Journal: New England Journal of Medicine (2003)

In the Clinical Practice article about early Alzheimer's disease, Dr. Kawas (Sept.11 issue) 1 discusses testing for reversible causes of dementia.More than 15 years ago, it was conclusively shown that true reversibility of dementia, especially in the elderly, was extremely rare. 2,3More recent work has confirmed these findings, revealing improvement in less than 1 percent of cases. 4 On the basis of the evidence, one should be quite conservative, and decisions about testing should be directed primarily by the clinical clues available from the history and physical examination.Kawas cites the American Academy of Neurology's universal neuroimaging policy but does not refer to other authoritative bodies that have published more conservative recommendations, such as those from Canada. 5 These guidelines have even been tested and found to do no harm. 6 Geriatricians long ago learned that it is often in the patient's best interest to make haste somewhat slowly.This is especially true in the case of a frail elderly patient who presents with cognitive decline.
Does β-Cell Autoimmunity Play a Role in Cystic Fibrosis–Related Diabetes? Analysis Based on the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry
Authors: Katja Konrad, Thomas Kapellen, Eggert Lilienthal, Nicole Prinz, Maria Bauer, Angelika Thon, Ernst Rietschel, Dagobert Wiemann, Reinhard W. Holl
Journal: Diabetes Care (2016)

Research on β-cell autoimmunity in cystic fibrosis (CF)-related diabetes (CFRD) is still rare. We aimed to analyze the frequency of β-cell autoimmunity and the influence on age at diabetes onset, insulin requirement, type of insulin therapy, and hypoglycemic or ketoacidotic events in patients with CFRD compared with antibody-negative patients with CFRD in the Diabetes Patienten Verlaufsdokumentation (DPV) registry.We analyzed data of 837 patients with CFRD in the German/Austrian DPV database by multivariable mixed-regression modeling.In our cohort, 8.5% of patients with CFRD (n = 72) were found to be β-cell antibody positive. There was a female preponderance in this patient group: 65.3 vs. 57.6%. Diabetes onset (median [interquartile range]) was earlier (14.00 [10.15-15.90] vs. 16.10 [13.50-21.20] years; P < 0.005), and insulin dose/kg body weight was higher (0.95 [0.61-1.15] vs. 0.67 [0.33-1.04] IU/kg; P < 0.05). There were also differences in the type of insulin treatment. Insulin pump therapy was used significantly more often in patients with CFRD with β-cell autoimmunity (18.2 vs. 6.4%; P < 0.05). The differences for multiple daily injections (ICT) and conventional therapy (CT) were not significant (ICT: 67.7 vs. 79.0%; CT: 15.2 vs. 14.6). Oral antidiabetic agents were rarely used in both groups. Rate of severe hypoglycemia with coma and rate of ketoacidosis were higher in antibody-positive patients (hypoglycemia with coma: 8.0 vs. 1.4, P < 0.05; ketoacidosis: 9.3 vs. 0.9, P < 0.05).Presence of β-cell autoantibodies in our cohort of patients with CFRD (8.5%) appeared to be greater than in the general population and was associated with female sex, earlier onset of diabetes, and higher insulin requirement. Insulin pump therapy was used significantly more often in patients with β-cell antibodies. Severe hypoglycemia and ketoacidosis were significantly more frequent in CFRD with β-cell autoimmunity compared with β-cell antibody-negative patients with CFRD.
Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes
Authors: R. Zambello, M. Facco, L. Trentin, R. Sancetta, C. Tassinari, A. Perin, A. Milani, G. Pizzolo, F. Rodeghiero, C. Agostini, R. Meazza, S. Ferrini, G. Semenzato
Journal: Blood (1997)
Transplant Therapy for Diabetes
Authors: J Stephenson
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal